Infectious Disease Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Infectious Disease Therapeutics Market By Drug class (Anti-Bacterial, Anti-Viral, Anti-Parasite, Anti-Fungal, Others), by disease indication (HIV/AIDS, Influenza, Hepatitis, Malaria, TB, Others), by Distribution channel (Hospital Pharmacy, Retail Pharmacy, Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Infectious Disease Therapeutics Market size valued USD 121.4 billion in 2021 and expected to reach USD 166.32 billion by 2028, at a CAGR of 4.6% during the forecast period 2022-2028. Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases are transmitted from one individual to other either by direct or indirect contact. The drugs used for infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps the body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others. Market players focus on mergers, acquisitions and collaborations to increase revenue share in the market. For instance, in August 2016, Pfizer acquired AstraZeneca’s late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in the infectious disease therapeutics market. Some of the pipeline anti-infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics market.

Key Developments:

In July 2017, Gilead’s “vosevi” oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus

In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections

In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.

Infectious Disease Therapeutics Market

MARKET SUMMARY
-
4.6%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 4.6%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Infectious Disease Therapeutics Market

  • The report on global infectious disease therapeutics market gives historical, current and future market sizes (US$ Mn) based on drug class, disease indication, distribution channel and geographical regions.
  • infectious disease therapeutics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Novartis AG.
  • AbbVie Inc.
  • AstraZeneca
Infectious Disease Therapeutics Market Dynamics

Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.


North-America Got Significant Share

Infectious Disease Therapeutics Market

Geographically market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the infectious disease therapeutics market owing to high prevalence rates of infectious diseases and rise in ageing population. According to scientific data from Princeton University 2015, rising trend in consumption of anti-infectives has increased in BRICS nation. In the last few years, there was an increase in use of antibiotics in Asian countries like India and China and some parts of Africa. Factors such as rapidly developing healthcare infrastructure on the grounds of emerging medical tourism industry along with government initiative to boost biotechnology sector of the respective country are fuelling the growth of the infectious disease therapeutics market in Asia Pacific region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Infectious Disease Therapeutics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

  1. Executive summary
  2. Global Infectious Disease Therapeutics Market Introduction
    • Global Infectious Disease Therapeutics Market– Taxonomy
    • Global Infectious Disease Therapeutics Market– Definitions
      • Drug Class
      • Disease Indication
  1. Global Infectious Disease Therapeutics Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Infectious Disease Therapeutics Market Dynamics – Factors Impact Analysis
    • Global Infectious Disease Therapeutics Market– Regulations
      • US
      • Europe
      • Japan
  1. Global Infectious Disease Therapeutics Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  2. Global Infectious Disease Therapeutics Market, By Drug Class, 2015 – 2019 and Forecast, 2020 – 2026
    • Anti-Bacterial
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-Viral
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-Parasite
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-Fungal
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Infectious Disease Therapeutics Market Forecast, By Disease Indication, 2015 – 2019 and Forecast, 2020 – 2026
    • HIV/AIDS
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Influenza
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Hepatitis
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Malaria
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Tuberculosis (TB)
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Infectious Disease Therapeutics Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026
    • Hospital Pharmacies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Infectious Disease Therapeutics Market Forecast, By Region, 2015 – 2019 and Forecast, 2020 – 2026
    • North America
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Infectious Disease Therapeutics Market- Opportunity Analysis Index – By Drug Class, By Disease Indication, By Distribution Channel, and Region, 2020 – 2026
  2. North America Infectious Disease Therapeutics Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Bacterial
      • Anti-Viral
      • Anti-Parasite
      • Anti-Fungal
      • Others
    • Disease Indication Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • HIV/AIDS
      • Influenza
      • Hepatitis
      • Malaria
      • TB
      • Others
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Infectious Disease Therapeutics Market- Opportunity Analysis Index – By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2020 – 2026
    • North America Infectious Disease Therapeutics Market Dynamics – Trends
  3. Europe Infectious Disease Therapeutics Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Bacterial
      • Anti-Viral
      • Anti-Parasite
      • Anti-Fungal
      • Others
    • Disease Indication Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • HIV/AIDS
      • Influenza
      • Hepatitis
      • Malaria
      • TB
      • Others
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Infectious Disease Therapeutics Market- Opportunity Analysis Index – By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2020 – 2026
    • Europe Infectious Disease Therapeutics Market Dynamics – Trends
  4. Asia-Pacific Infectious Disease Therapeutics Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Bacterial
      • Anti-Viral
      • Anti-Parasite
      • Anti-Fungal
      • Others
    • Disease Indication Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • HIV/AIDS
      • Influenza
      • Hepatitis
      • Malaria
      • TB
      • Others
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Infectious Disease Therapeutics Market- Opportunity Analysis Index – By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2020 – 2026
  • Asia-Pacific Infectious Disease Therapeutics Market Dynamics – Trends
  1. Latin America Infectious Disease Therapeutics Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Bacterial
      • Anti-Viral
      • Anti-Parasite
      • Anti-Fungal
      • Others
    • Disease Indication Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • HIV/AIDS
      • Influenza
      • Hepatitis
      • Malaria
      • TB
      • Others
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Infectious Disease Therapeutics Market- Opportunity Analysis Index – By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2020 – 2026
    • Latin America Infectious Disease Therapeutics Market Dynamics – Trends
  2. Middle East & Africa Infectious Disease Therapeutics Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Bacterial
      • Anti-Viral
      • Anti-Parasite
      • Anti-Fungal
      • Others
    • Disease Indication Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • HIV/AIDS
      • Influenza
      • Hepatitis
      • Malaria
      • TB
      • Others
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Infectious Disease Therapeutics Market- Opportunity Analysis Index – By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2020 – 2026
    • MEA Infectious Disease Therapeutics Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • GlaxoSmithKline Plc (U.K.)
      • Johnson & Johnson Services, Inc. (U.S.)
      • Merck & Co, Inc. (U.S.)
      • Pfizer Inc. (U.S.)
      • Novartis AG. (Switzerland)
      • AbbVie Inc. (U.S.)
      • Astellas Pharma Inc. (Japan)
      • AstraZeneca (U.K.)
      • Auritec Pharmaceuticals Inc. (U.S.)
      • Bayer AG (Germany)
      • Chimerix Inc. (U.S.)
  4. Research Methodology
  5. Key Assumptions and Acronyms


Report

Company Profile

  • GlaxoSmithKline Plc (U.K.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Merck & Co, Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Novartis AG. (Switzerland)
  • AbbVie Inc. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca (U.K.)
  • Auritec Pharmaceuticals Inc. (U.S.)
  • Bayer AG (Germany)
  • Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.)
  • Chimerix Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Isis Pharmaceuticals (U.S.)
  • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan)
  • Sanofi S.A. (France)
  • Gilead Sciences (U.S.)

Description

Infectious Disease Therapeutics Market size valued USD 121.4 billion in 2021 and expected to reach USD 166.32 billion by 2028, at a CAGR of 4.6% during the forecast period 2022-2028. Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases are transmitted from one individual to other either by direct or indirect contact. The drugs used for infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps the body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others. Market players focus on mergers, acquisitions and collaborations to increase revenue share in the market. For instance, in August 2016, Pfizer acquired AstraZeneca’s late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in the infectious disease therapeutics market. Some of the pipeline anti-infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics market.

Key Developments:

In July 2017, Gilead’s “vosevi” oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus

In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections

In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal quadrivalent (Influenza Vaccine) for adults.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX